Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
Issued Date
2023-06-01
Resource Type
eISSN
19994923
Scopus ID
2-s2.0-85163790548
Journal Title
Pharmaceutics
Volume
15
Issue
6
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pharmaceutics Vol.15 No.6 (2023)
Suggested Citation
Basu A., Namporn T., Ruenraroengsak P. Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma. Pharmaceutics Vol.15 No.6 (2023). doi:10.3390/pharmaceutics15061611 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87933
Title
Critical Review in Designing Plant-Based Anticancer Nanoparticles against Hepatocellular Carcinoma
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Hepatocellular carcinoma (HCC), accounting for 85% of liver cancer cases, continues to be the third leading cause of cancer-related deaths worldwide. Although various forms of chemotherapy and immunotherapy have been investigated in clinics, patients continue to suffer from high toxicity and undesirable side effects. Medicinal plants contain novel critical bioactives that can target multimodal oncogenic pathways; however, their clinical translation is often challenged due to poor aqueous solubility, low cellular uptake, and poor bioavailability. Nanoparticle-based drug delivery presents great opportunities in HCC therapy by increasing selectivity and transferring sufficient doses of bioactives to tumor areas with minimal damage to adjacent healthy cells. In fact, many phytochemicals encapsulated in FDA-approved nanocarriers have demonstrated the ability to modulate the tumor microenvironment. In this review, information about the mechanisms of promising plant bioactives against HCC is discussed and compared. Their benefits and risks as future nanotherapeutics are underscored. Nanocarriers that have been employed to encapsulate both pure bioactives and crude extracts for application in various HCC models are examined and compared. Finally, the current limitations in nanocarrier design, challenges related to the HCC microenvironment, and future opportunities are also discussed for the clinical translation of plant-based nanomedicines from bench to bedside.